Indications
Wayrilz is indicated for the treatment of immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (see section 5.1)
Composition
- Active substance
- rilzabrutinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Wayrilz
- Active substance
- rilzabrutinib
- ATC code
- Not yet assigned
- Group
- Nervous system
- Therapeutic area
- Purpura, Thrombocytopenic, Idiopathic
- Marketing authorisation holder
- Sanofi B.V.
- Status
- Authorised
- EU authorisation
- 22 Dec 2025